Increasing Incidence of Communicable and Noncommunicable Diseases Boost Market Growth
The incidence of several communicable and noncommunicable diseases has increased exponentially in the last few years, mainly due to the unhealthy lifestyle of the modern world. Smoking, infections, and genetic factors can cause serious respiratory complications, cardiovascular disorders, and bacterial and viral infections, etc. These diseases are among the medical conditions exerting a huge burden on the public healthcare system in various countries. Per the data by the WHO, ~10 million cases of tuberculosis are observed every year and all of them are diagnosed using a tuberculin skin test, which involves the use of intradermal injections. Several studies suggest that intradermal injections could improve the absorption of various anticancer and immunological drugs, and they can also be used to deliver gene therapies. Tropis ID of Pharmajet, one of the Novel intradermal injection devices, offers prominent results in delivering various drugs targeting a wide range of diseases.
Market Overview
The UK, Germany, France, Italy, Spain, and the Rest of Europe are the key contributors to the intradermal injections market in Europe. Germany dominates the market in this region. Various medical players in Germany manufacture cost-effective products with superior quality. Germany is the second largest market for medical devices after the US. According to AIM, an IGES Group company, the medical device market in Germany is valued at US$ 28.25 billion (25 billion euros). Additionally, the government in the country has made health insurance mandatory for citizens. ~71.4 million people in Germany are covered by Gesetzliche Krankenversicherung (GKV), which is a public health insurance, and ~8.8 million people are covered by the Private Krankenversicherung (PKV) through state aid, which is a private health insurance. According to the WHO data, the detection rate of tuberculosis cases was ~87% in 2020. Further, the incidence rate of tuberculosis in Germany is ~5.5 per 100,000 population, which indicates the elevating need for intradermal injections. The expanding elderly population and the rising prevalence of allergic reactions are also propelling the German market for intradermal injections. The country has more than 400 hospitals dedicated to the geriatric population. Therefore, the demand for advanced medical equipment, such as needle-free injections, is high in this country. With the high acceptance of cosmetic procedures, the use of intradermal injections in aesthetic procedures is also on rise in the country. Grabbing these opportunities, Germany invests significantly in healthcare research and infrastructure. According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015. Along with this, various leading companies are investing in medical device manufacturing in Germany.
Europe Intradermal Injections Market Revenue and Forecast to 2028 (US$ Million)
Europe Intradermal Injections Market Segmentation
The Europe intradermal injections market is segmented on the basis of method, application, end user, and country.
Based on method, the market is segmented into normal sized needle, short needle, and without needle. The normal sized needles segment registered the largest market share in 2021. The normal sized needles segment is further sub segmented into intradermal microinjections, microneedle arrays, and tattoo devices. The short needle segment is bifurcated into intradermal liquid jet injectors and ballistic intradermal injectors.
In terms of application, the Europe intradermal injections market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held the largest market share in 2021.
The Europe intradermal injections market, by end user, is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held the largest market share in 2021.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and rest of Europe. Germany dominated the market in 2021.
BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; EUNSUNG GLOBAL; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd are the leading companies operating in intradermal injections market in the Europe region.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,029.42 Million |
| Market Size by 2028 | US$ 2,131.06 Million |
| CAGR (2021 - 2028) | 11.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Method
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Intradermal Injections Market is valued at US$ 1,029.42 Million in 2021, it is projected to reach US$ 2,131.06 Million by 2028.
As per our report Europe Intradermal Injections Market, the market size is valued at US$ 1,029.42 Million in 2021, projecting it to reach US$ 2,131.06 Million by 2028. This translates to a CAGR of approximately 11.0% during the forecast period.
The Europe Intradermal Injections Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Intradermal Injections Market report:
The Europe Intradermal Injections Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Intradermal Injections Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Intradermal Injections Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Intradermal Injections Market
